Paper Details

  1. Home
  2. Paper Details

Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.

Author: AndreisDaniele, De RosaFrancesco, FarnetaniFrancesca, FocaFlavia, MagiSerena, MandelVictor Desmond, ManganoniAusilia Maria, MazzoniLaura, MedriMatelda, PallaMarco, PavoniLaura, RiberoSimone, StanganelliIgnazio, UliviPaola

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

Skin adverse events related to vemurafenib were common, with 45 out of 62 patients experiencing at least one event. Long-term survivors tended to experience less frequent and severe skin adverse events.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The introduction of targeted therapies for the treatment of BRAF-mutated metastatic melanoma was associated with different cutaneous adverse events (AEs). OBJECTIVES: To describe the type, frequency and severity of cutaneous AEs related to vemurafenib; to understand the association betw...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/09546634.2020.1817838

データ提供：米国国立医学図書館（NLM）

Vemurafenib: A Powerful Weapon in the Battle Against Melanoma

Melanoma is a formidable foe, lurking in the shadows of the skin like a desert predator. This research explores the use of vemurafenib, a targeted therapy, in the treatment of advanced melanoma.

A Targeted Approach to Treatment

The study investigated the cutaneous toxicity and prognostic implications of long-term vemurafenib therapy in patients with advanced melanoma harboring the BRAF V600E mutation. The results showed that vemurafenib was effective in controlling melanoma, but it was associated with some cutaneous side effects. This is like using a precise weapon to target a specific enemy, but it can also have collateral damage. However, the researchers found that the presence of certain skin side effects might even be a positive prognostic indicator, suggesting that these side effects may be a sign of effective treatment.

Navigating the Side Effects

This research highlights the importance of careful monitoring and management of cutaneous side effects in patients receiving vemurafenib. It's like navigating a desert with dangerous terrain, requiring vigilance and adaptability to minimize potential hazards. By understanding the potential risks and benefits of vemurafenib, we can ensure a safe and effective journey through melanoma treatment.

Dr.Camel's Conclusion

This research provides valuable insights into the use of vemurafenib in the treatment of advanced melanoma. By understanding the potential side effects and their implications, we can better manage this challenging disease and improve outcomes for our patients. It is a testament to the power of targeted therapy and the ongoing search for new weapons in the battle against cancer.

Date :
  1. Date Completed 2022-06-09
  2. Date Revised 2022-06-17
Further Info :

Pubmed ID

32875931

DOI: Digital Object Identifier

10.1080/09546634.2020.1817838

Related Literature

Article Analysis
・Side Effects of vemurafenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.